



רופא/ה יקר/ה,

חטיבת סנדוז בחברת נוברטיס ישראל שמחה לבשר לך על השקת היירימוז, שהינו תכשיר ביוסימילארי ליומירה¹. היירימוז מכיל את החומר הפעיל אדאלימומאב ומשוקק בשתי פרזנטציות²:

עט סנסורדי מוכן לשימוש | Hyrimoz 40 mg pre-filled pen*


הפעלת הזרקה באמצעות הצמדה כנגד העור, ללא שימוש בכפתור ("buttonless injection")^{1,2}



חיווי כפול להתקדמות הזרקה²:
- חיווי ויזואלי - חלונית צפיה שקופה של 360°
- חיווי קולי - נקישה בתחילת וסיום ההזרקה

אחיזה נוחה - הודות לצורתו המשולשת של העט²

מזרק מוכן לשימוש | Hyrimoz 40 mg pre-filled syringe*



HYRIMOZ[®] - ADALIMUMAB BIOSIMILAR BY SANDOZ

היירימוז נרשם ב-FDA וב-EMA³ על בסיס הוכחת קומפרביליות בשורה נרחבת של בדיקות אנליטיות ומחקרים קליניים. הפרסומים העיקריים המציגים את מחקרי הפאזה השלישית של היירימוז, הינם ה-ADACCESS⁴, ה-ADMYRA⁵ ופרסום אודות ה-patient reported outcome measures³. היירימוז מאושר בישראל להתוויות הבאות⁶:

Rheumatoid arthritis

Hyrimoz in combination with methotrexate is indicated for: ♦ The treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. ♦ The treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Hyrimoz can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate. **Axial spondyloarthritis Ankylosing spondylitis (AS):** Hyrimoz is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. **Axial spondyloarthritis without radiographic evidence of AS:** Hyrimoz is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS, but with objective signs of inflammation by radiological and/or laboratory tests including MRI and serum CRP levels, who have had an inadequate response to, or are intolerant to, non-steroidal anti-inflammatory drugs. **Psoriatic arthritis** Hyrimoz is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. Adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease and to improve physical function. **Psoriasis** Hyrimoz is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. **Hidradenitis suppurativa (HS)** Hyrimoz is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adult patients with an inadequate response to conventional systemic HS therapy. **Crohn's disease** Hyrimoz is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy. Hyrimoz is indicated for reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab. **Ulcerative colitis** Hyrimoz is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies. **Uveitis** Hyrimoz is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. **Intestinal Behcet's disease** Hyrimoz is indicated for the treatment of intestinal Behcet's disease in patients who have had an inadequate response to conventional therapy.

סנדוז מציעה תוכנית הדרכה להזרקה נכונה עבור המטופלים של היירימוז. לסרטון הדרכה להזרקה נכונה של היירימוז בעט סנסורדי לחץ כאן: [📺](#) קוד כניסה 0101 לעלון לרופא לחץ כאן: [📄](#)

ליצירת קשר
☎ 054-5211409 ✉ irit.starobin@sandoz.com

לעדכונכם בברכה,
אירית סטרובין, מנהלת המוצר

*adalimumab 40 mg / 0.8 ml
References: 1. Hyrimoz patient leaflet as approved in Israel. 2. Tischer and Mehl. Patients' and nurses' preferences for autoinjectors for rheumatoid arthritis: results of a European survey. Patient Preference and Adherence 2018;12:1413-1424. 3. Blauvelt A, et al. Treatment with SDZ ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient Preference and Adherence from Two Phase III Studies (ADMYRA and ADACCESS). BioDrugs; March 2021. 4. Blauvelt A, et al. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. British Journal of Dermatology (2018) 179, pp623-631. 5. Wiland P, et al. Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study. BioDrugs (2020) 34:809-823. 6. Hyrimoz prescribing information leaflet as approved in Israel.